Search results for "luteinizing hormone"

showing 10 items of 75 documents

Inverse correlation between baseline inhibin B and FSH after stimulation with GnRH: a study of serum levels of inhibin A and B, pro alpha-C and activ…

2000

OBJECTIVE: Interest has focused recently on the influences of the polypeptide factors inhibin and activin on the selective regulation of the pituitary secretion of gonadotropins. DESIGN: Measurement of the concentrations of inhibin-related proteins in relation to the changes in pituitary gonadotropin (FSH, LH) parameters, after GnRH stimulation with a bolus injection of 100 microg gonadorelin, in 19 women with ovulatory disturbances. METHODS: Serum levels of inhibin A and B, activin A, and pro alpha-C were measured using sensitive ELISA kits. RESULTS: Within 60 min after GnRH stimulation, FSH values doubled from 5 to 10 mU/ml (P < 0.001). LH increased 12-fold from 2 to 24 mU/ml (P < 0…

Adultendocrine systemmedicine.medical_specialtyInhibin aAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismAlpha (ethology)StimulationGonadotropin-releasing hormoneGonadotropin-Releasing HormoneFollicle-stimulating hormoneEndocrinologyInternal medicinemedicineHumansInhibinsOvarian DiseasesAmenorrheaEstradiolChemistryHypogonadismGeneral MedicineLuteinizing HormoneActivinsEndocrinologyAmenorrheaFemaleGonadotropinmedicine.symptomFollicle Stimulating HormoneLuteinizing hormonehormones hormone substitutes and hormone antagonistsHypothalamic DiseasesEuropean journal of endocrinology
researchProduct

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vi…

2007

Objective: To investigate the effects of recombinant (r-) LH supplementation in “low responder” patients undergoing ovarian stimulation with r-FSH for an IVF program. The apoptosis rate in cumulus cells was used as an indicator of oocyte quality. Design: Comparison of the rate of DNA fragmentation and caspase-3 activity in cumulus cells in women stimulated with r-LH and r-FSH, versus patients treated with r-FSH alone (control). Setting: In vitro fertilization (IVF) laboratory. Patient(s): Forty patients undergoing assisted fertilization programs treated with a GnRH agonist, or r-FSH treatment begun on day 3 of the cycle (control). In the r-LH group, from day 8 of gonadotropin stimulation, 1…

Adultendocrine systemmedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentOvaryApoptosisDNA FragmentationFertilization in VitroBiologyOvulation InductionPregnancyInternal medicinemedicineIn Situ Nick-End LabelingHumansrecombinant LHOvarian follicleimplantation rateHuman cumulus cells; apoptosis; IVF; pregnancy rate; implantation rate; recombinant LH; oocyte qualityIn vitro fertilisationGranulosa CellsCaspase 3Obstetrics and GynecologyLuteinizing HormoneOocyteCumulus oophorusapoptosiRecombinant ProteinsPregnancy ratemedicine.anatomical_structureEndocrinologyHuman cumulus cellReproductive MedicineIVFFemaleoocyte qualityGonadotropinFollicle Stimulating HormoneLuteinizing hormonehormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist.

2011

High daily doses of gonadotrophin-releasing hormone (GnRH) antagonists during the follicular phase of ovarian stimulation were associated with low implantation rates. To test if this occurred because of profound pituitary suppression, the pituitary response was suppressed with a high-dose GnRH antagonist and recombinant LH (rLH) was added back to correct the implantation rate. An open-label, randomized, controlled, prospective clinical study in 60 patients undergoing IVF was performed. GnRH antagonist was initiated on day 6 of stimulation (2 mg/day) together with 375 IU rLH, and maintained until the day of HCG administration. Controls received 0.25 mg/day GnRH antagonist. Fluctuating LH con…

Adultendocrine systemmedicine.medical_specialtymedicine.medical_treatmentStimulationlaw.inventionGonadotropin-Releasing HormoneOvulation InductionlawInternal medicineFollicular phaseMedicineHumansProspective StudiesAdverse effectProspective cohort studyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyLuteinizing HormoneRecombinant ProteinsDose–response relationshipEndocrinologyReproductive MedicineRecombinant DNAOvulation inductionFemalebusinesshormones hormone substitutes and hormone antagonistsDevelopmental BiologyHormoneReproductive biomedicine online
researchProduct

Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ova…

1995

Objective To determine if the somatostatin analog, octreotide, affects insulin and related peptides and, hence, androgen levels differently between polycystic ovary syndrome (PCOS) patients and controls. Design Prospective controlled trial. Setting Reproductive endocrinology clinic of our medical center. Patients Eleven women with PCOS and six matched ovulatory controls. Interventions Octreotide (100 μg) was administered subcutaneously in the midfollicular phase. Serum was obtained before and at 60, 120, 180, and 240 minutes after octreotide. Main Outcome Measures Fasting insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), T, androstenedion…

Adultmedicine.medical_specialtyAdolescentendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentOctreotideBiologyOctreotideInsulin-like growth factor-binding proteinInternal medicinemedicineHumansInsulinTestosteroneProspective StudiesInsulin-Like Growth Factor ITestosteronePancreatic hormoneInsulinAndrostenedioneObstetrics and GynecologyFastingLuteinizing HormoneAndrogenPolycystic ovaryInsulin-Like Growth Factor Binding ProteinsSomatostatinEndocrinologyReproductive Medicinebiology.proteinFemaleCarrier ProteinsPolycystic Ovary Syndromemedicine.drugFertility and Sterility
researchProduct

Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major

2002

We studied bone mass and metabolism in 30 adult women (age 28.5 +/- 1.3) with thalassemia major (TM) and evaluated whether prolonged hormone replacement therapy (HRT) was able to optimize bone accrual. TM patients had reduced bone mass, increased bone turnover and lower serum gonadotropin and estradiol levels compared with 10 normal women of similar age. A significant correlation was found between bone mass and sex hormone levels. Six TM patients with normal ovarian function had normal bone turnover markers and modestly low bone mass (lumbar spine -1.29 +/- 0.31; femoral neck -0.60+/-0.21; Z-score). The other 24 TM women were hypogonadic and had significantly lower bone mass for age (lumbar…

Adultmedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and MetabolismThalassemiaOsteoporosisBone remodelingAdult womenEndocrinologySex hormone-binding globulinBone DensityInternal medicinemedicineHumansOrthopedics and Sports MedicineFemoral neckEstradiolbiologybusiness.industryHypogonadismbeta-ThalassemiaOsteoporosiLuteinizing Hormonemedicine.diseaseThalassaemiaEndocrinologymedicine.anatomical_structureTransgender hormone therapyOrthopedic surgerybiology.proteinFemaleFollicle Stimulating HormonebusinessCalcified Tissue International
researchProduct

Neuromuscular adaptations and serum hormones in females during prolonged power training.

1990

Training-induced adaptations in the neuromuscular and endocrine systems were investigated in seven females during prolonged power type strength training. Great (p less than 0.05) changes occurred primarily during the earlier weeks of the 16-week training especially in the time of force production (from 161 +/- 107 to 93 +/- 65 ms to produce a 500 N force) and, correspondingly, in the average forces in the earlier positions of the (absolute) force-time curve of the leg extensor muscles. These changes were accompanied by significant (p less than 0.05) increases in the neural activation of the trained muscles in the earliest positions of the IEMG-time curve. Hypertrophic changes, as judged fro…

Adultmedicine.medical_specialtyStrength trainingBiopsyPhysical ExertionNeuromuscular JunctionPhysical Therapy Sports Therapy and RehabilitationElectromyographyMuscle hypertrophyFollicle-stimulating hormoneSex hormone-binding globulinInternal medicineEndocrine GlandsmedicineHumansOrthopedics and Sports MedicineTestosteronePhysical Education and Trainingbiologymedicine.diagnostic_testbusiness.industryElectromyographyMusclesHypertrophyAdaptation PhysiologicalHormonesEndocrinologybiology.proteinFemaleLuteinizing hormonebusinessHormoneInternational journal of sports medicine
researchProduct

Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endo…

2003

OBJECTIVE: The present study aims at demonstrating the equivalence of the 28-day and 3-month formulations of triptorelin SR (sustained release) in terms of percentage of patients achieving castration levels of estradiol (<==50 pg/mL) 84 days after treatment initiation. DESIGN: A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis. SETTING: Academic hospitals. PATIENT(S): Seventy-two women with endometriosis. were treated with a single intramuscular injection of 3-month triptorelin SR, and 74 patients were treated with one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months. INTERVENTION(S): As pa…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classChemistry PharmaceuticalPopulationEndometriosisUrologyEndometriosisInjections IntramuscularDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawRecurrenceestrogenmedicineHumanseducationGynecologyeducation.field_of_studyTriptorelin PamoateEstradiolDecapeptylbusiness.industryendometriositriptorelinObstetrics and GynecologyMedical castrationLuteinizing Hormonemedicine.diseaseTriptorelinLuteolytic AgentsCastrationReproductive MedicinechemistryEstrogenPharmacodynamicsFemaleFollicle Stimulating HormoneIntramuscular injectionbusinessmedicine.drugFertility and sterility
researchProduct

Characteristics of urinary luteinizing hormone (LH) during the induction of LH surges of different magnitude in blood

1995

Urinary luteinizing hormone (LH) testing has been proposed as a reliable method for the prediction of ovulation but its accuracy has been challenged by some studies. To check how accurately the oscillations of urinary LH reflected the plasma changes, surges of LH of different magnitude and duration were artificially induced in plasma and the hormone was measured simultaneously in urine. Post-menopausal women (n = 16) were stimulated during 1 week with a combination of transdermal oestradiol (400 micrograms) and i.m. progesterone (25 mg on day 4, 50 mg on day 5) to obtain an LH discharge comparable with the pre-ovulatory LH peak. A short and moderate peak of LH was induced by the i.v. inject…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classmedia_common.quotation_subjectRadioimmunoassayGonadotropin-releasing hormoneUrineBuserelinSensitivity and SpecificityGonadotropin-Releasing HormoneAndrologyInternal medicinemedicineHumansOvulationProgesteronemedia_commonOvulation DetectionEstradiolChemistryEstrogen Replacement TherapyRehabilitationReproducibility of ResultsObstetrics and GynecologyLuteinizing HormoneMiddle Agedmedicine.diseaseBuserelinMenopauseEndocrinologyReproductive MedicineFemaleMenopauseGonadotropinLuteinizing hormonemedicine.drugHormoneHuman Reproduction
researchProduct

Neuromuscular and hormonal responses in elite athletes to two successive strength training sessions in one day

1988

Acute neuromuscular and endocrine adaptations to weight-lifting were investigated during two successive high intensity training sessions in the same day. Both the morning (I) (from 9.00 to 11.00 hours) and the afternoon (II) (from 15.00 hours to 17.00 hours) training sessions resulted in decreases in maximal isometric strength (p less than 0.01 and less than 0.05), shifts (worsening) in the force-time curve in the absolute scale (p less than 0.05 and ns.) and in decreases in the maximal integrated EMG (p less than 0.01 and less than 0.05) of the selected leg extensor muscles. Increases in serum total (p less than 0.05) and free testosterone (p less than 0.01) and in cortisol (p less than 0.…

Adultmedicine.medical_specialtyWeight LiftingPhysiologyStrength trainingPhysical ExertionIsometric exerciseElectromyographySex hormone-binding globulinIsometric ContractionSex Hormone-Binding GlobulinPhysiology (medical)Internal medicinemedicineHumansTestosteroneOrthopedics and Sports MedicineTestosteroneHydrocortisoneMorningLegPhysical Education and Trainingbiologymedicine.diagnostic_testElectromyographybusiness.industryMusclesPublic Health Environmental and Occupational HealthBlood ProteinsGeneral MedicineLuteinizing HormoneHormonesEndocrinologyGrowth HormoneLactatesbiology.proteinbusinessLuteinizing hormoneMuscle ContractionSportsmedicine.drugEuropean Journal of Applied Physiology and Occupational Physiology
researchProduct

Hormonal and molecular characterization of follicular fluid, cumulus cells and oocytes from pre-ovulatory follicles in stimulated and unstimulated cy…

2012

background: The use of ovarian stimulation, to stimulate a multi-follicular response for assisted reproduction treatments, may force the production of oocytes from follicles that do not reach optimal maturation, possibly yielding oocytes that are not fully competent. The present study aimed to define the follicular environment and oocyte competence of unstimulated pre-ovulatory follicles, to compare it with that of similar-sized stimulated follicles. For this purpose, we analyzed the follicular hormonal milieu, the oocyte meiotic spindle, the embryo development and the cumulus cells gene expression (GE) profiles. methods and results: The study population was divided in two groups: (i) 42 oo…

Adultmedicine.medical_specialtymedia_common.quotation_subjectGene ExpressionBiologyOvarian FollicleOvulation InductionInternal medicineFollicular phasemedicineHumansTestosteroneRNA MessengerSperm Injections IntracytoplasmicOvarian follicleOvulationProgesteronemedia_commonCumulus CellsEstradiolReverse Transcriptase Polymerase Chain ReactionRehabilitationAndrostenedioneObstetrics and GynecologyEmbryoLuteinizing HormoneEmbryo MammalianMicroarray AnalysisOocyteFollicular fluidCumulus oophorusHormonesFollicular FluidMeiosismedicine.anatomical_structureEndocrinologyReproductive MedicineOocytesFemaleFolliculogenesisFollicle Stimulating HormoneHuman Reproduction
researchProduct